Mental Health

The survey reported that approximately 65% of participants were concerned about their mental health, which is a 15% increase since 2020.

This is the first FDA advisory committee meeting that will review a potential new posttraumatic stress disorder treatment in 25 years.

The story of gepirone may spark new conversations for industry standards on drug development to facilitate future innovations.

A new treatment for postpartum depression has been developed with rapid onset, cutting down the time it has taken previous treatments to take effect by weeks or months.

Compared with women who aren’t experiencing menopausal symptoms, women in the perimenopause stage were approximately 40% more likely to experience depressive symptoms.

This expansion of their role goes beyond traditional dispensing duties, positioning pharmacists as an essential bridge between patients and the broader health care system.

Patients who were formerly incarcerated commonly experience substance use disorder, tuberculosis, hepatitis C, and sexually transmitted diseases

The study is the first of 5 studies co-published by AYR Wellness and LECOM and showcases improvements in physical, social, and mental well-being with minimal AEs.

The campaign for National Stress Awareness Month in April is under way.

However, psychedelic medicine has a variety of barriers, including historical perception, access challenges, legal obstacles, and ethical questions.

Pharmacists should be well educated on prescription digital therapeutics to better educate patients on software in comparison to traditional pharmacological products.

Pharmacists can address social determinants to improve patient well-being and treatment.

Social determinants of health can worsen mental health disorders such as depression, but the effect of depression can also negatively impact social determinants of health.

Current evidence and data regarding clozapine-resistant schizophrenia is unclear, but new treatment options are on the horizon that could show promise.

Guidance on evaluating contraceptive options for patients with psychiatric conditions

Data for generalized anxiety disorders and cannabis use is scarce, but pharmacists can help educate patients on potential benefits and risks of cannabis usage.

Developments in glycine transporter type 1 inhibitors, D-amino acid oxidase inhibitors, and phosphodiesterase inhibitors are pushing schizophrenia research forward.

Pharmacy Times will be at the American Association of Psychiatric Pharmacists (AAPP) Annual Meeting in Orlando, Florida from April 7 to April 10, 2024.

MDMA-assisted therapy and psilocybin currently lead the way with potential approvals by the FDA.

Investigators also found that African American and White veterans had different risk factors for re-hospitalization post-stroke.

This holistic approach to healing, grounded in harnessing the therapeutic properties of plants, serves as a bridge between centuries-old traditional wisdom and modern scientific practices.

Health care professionals providing care to patients using second-generation antipsychotics could benefit from incorporating community pharmacists as members of their team.

Investigators aimed to determine the impact of psychotherapy or psychopharmacologic treatments on adverse outcomes in individuals with coronary artery disease or heart failure.

Psychedelic medicines such as psilocybin, MDMA, ketamine, and LSD have been shown to have a significant impact on conditions such as major depressive disorder, generalized anxiety disorder, and post-traumatic stress disorder in clinical trials.

These therapies can improve treatment adherence for patients, especially for those with a history of poor or uncertain adherence.

Sa'ed Al-Olimat, PharmD, also discussed the potentially groundbreaking shift for MDMA expected later in 2024.

Pharmacogenomics could help streamline prescribing and dosing for psychiatric medications, avoiding the trial-and-error process common with these medications.

Pharmacists can educate patients on current clinical evidence of cannabis’s therapeutic benefit, as well as cannabis’s complexities, risks, and potential adverse effects.

At 4 months, 75% of participants achieved remission and no longer showed signs of depression symptoms in a phase 2 clinical trial.

Case reports have shown a potential association with adverse psychological effects.